[link removed]
[link removed] [link removed]
View web version ([link removed])
[link removed]
In advance of crucial meeting, Biogen’s Alzheimer’s drug wins praise from FDA
Biogen’s closely watched experimental drug for Alzheimer’s disease got a boost Wednesday after reviewers for the Food and Drug Administration said it appeared to be safe and effective.

The assessments propelled the Cambridge biotech’s stock up by more than 40 percent, two days before an FDA advisory committee is expected to meet on whether to recommend that the full agency approve aducanumab.

If the drug were approved, it would be the first new Alzheimer’s drug in nearly two decades. It would also be a remarkable reversal of fortunes for Biogen, which specializes in medicines to treat neurological conditions.

Read the full story. ([link removed])
------------------------------------------------------------
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])
------------------------------------------------------------
[link removed]
[link removed] [link removed]

============================================================
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2020 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)